The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2015 | Acute leukemia: epidemiology and progress in treatment
Elias Jabbour, MD from the University of Texas MD Anderson Cancer Center, Houston, TX talks about the different forms of acute leukemia, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). He explains the importance of knowing which subset of acute leukemia a patient is affected by and referring patients with AML or ALL to experts. He also discusses the advancements in treatments that have been made, such as the development of rituximab, and the difference these developments have made for survival rates in patients with, for example, Burkitt lymphoma.
Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, at Orlando, FL.
